Currently, PD-L1 immunohistochemistry (IHC) and tumor mutational burden (TMB) are approved by the FDA as companion diagnostics for immunotherapy, although neither modality has shown a correlation to outcome in all cases [77,78,79]. The gene discussed is CD274; the disease is neoplasm.